Quick Summary

Amla (Phyllanthus emblica) is a plant widely studied for its potential antioxidant, anti-inflammatory, hypolipidemic, and hypoglycemic properties. Available clinical trial evidence suggests that amla extract may improve lipid profiles by reducing total cholesterol and LDL-C, increasing HDL-C, and may have beneficial effects on blood glucose and systemic inflammation. Preliminary safety data indicate that amla supplementation is generally well tolerated with mild or no reported adverse events. However, clinical evidence is limited by small sample sizes, study heterogeneity, and low certainty of evidence.

What is it?

Amla, also known as Indian gooseberry, is the fruit of the tree Phyllanthus emblica. It has a long history of use in traditional medicine, particularly in Ayurveda, and is valued for its vitamin C content and other bioactive compounds.

Traditional Uses

Traditionally, amla has been used in Ayurvedic medicine for supporting digestive health, enhancing immunity, and promoting skin and hair wellness. It is also used as a general tonic and for its purported anti-inflammatory and rejuvenating effects.

Active Compounds

Amla contains various bioactive compounds including vitamin C, tannins, flavonoids, and polyphenols. These constituents are thought to contribute to its antioxidant and anti-inflammatory properties.

Potential Benefits with Evidence Levels

  • Dyslipidemia and Cardiovascular Risk Factors (Moderate to Low): Systematic reviews and meta-analyses of randomized controlled trials report significant reductions in total cholesterol and LDL-C, along with increases in HDL-C, with amla fruit extract compared to placebo. Effects on triglycerides are less consistent. Evidence is limited by high heterogeneity and the small number of trials.
  • Hyperglycemia and Metabolic Parameters (Preliminary Clinical Evidence): Some meta-analyses suggest that amla supplementation may lower fasting blood glucose and C-reactive protein levels, indicating potential antihyperglycemic and anti-inflammatory effects. These findings require confirmation in larger, more rigorous trials.
  • Oxidative Stress and Inflammation (Preliminary Clinical Evidence): Emerging evidence from randomized controlled trials, including studies in post-COVID-19 populations, suggests that amla-containing formulations may reduce markers of oxidative stress and systemic inflammation, although consistent between-group differences have not been demonstrated.
  • Hypercholesterolemia and Lipid Management (General Herbal Intervention Context) (Pending Systematic Review): Herbal interventions including amla are being evaluated for lipid-lowering effects; preliminary protocols indicate possible favorable modulation of cholesterol profiles, but data specific to amla await comprehensive synthesis.
  • Adjunctive Use in Metabolic Syndrome (Preliminary Evidence): A study combining amla extract with olive extract in hyperlipidemic adults with type 2 diabetes or prediabetes showed reductions in glycemia levels without reported safety concerns.

Side Effects

Reported side effects are mostly mild and infrequent, primarily including gastrointestinal symptoms such as dyspepsia. No serious adverse events have been reported in clinical trials to date. Data on long-term safety remain limited.

Drug Interactions

There are no clinical data on specific drug interactions with amla. However, caution is advised due to the potential for additive effects when combined with lipid-lowering or blood glucose-lowering medications. Further research is needed to clarify interaction risks.

Who Should Avoid It

Specific contraindications for amla have not been well established. Traditional use suggests caution during pregnancy and breastfeeding due to insufficient safety data. Use during these periods is not recommended without medical supervision.

Evidence Limitations

  • Limited number of randomized controlled trials specifically evaluating standardized amla extracts.
  • High heterogeneity in study designs, populations, dosages, and outcome measures.
  • Small sample sizes and short intervention durations in most clinical trials.
  • Lack of large-scale, long-term, multicenter randomized controlled trials.
  • Some meta-analyses report high statistical heterogeneity reducing certainty of pooled estimates.
  • Limited data on herb-drug interactions and long-term safety profiles.
  • Predominantly studies conducted in age groups 40-58 years; generalizability to other populations is not established.
  • Several studies report only mild or no adverse events, making detection of rare adverse effects challenging.

References

Last Reviewed

June 2024

Disclaimer

This information is provided for educational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before starting any new supplement, especially if you have underlying health conditions or are taking medications.